China to step up anti-monopoly operations in pharmaceutical business
1 Min Read
Law enforcement has plans to combat monopolistic activities and create a favorable business environment.
-
China leads in the manufacturing and exporting of active medicinal ingredients (Pharmaceutical-tech.com)
According to the Chinese Ministry of Industry and Information Technology, China's law enforcement is planning on combatting monopolistic activities and unfair competition in the pharmaceutical industry as the government strives to create a favorable business environment.
The move is in response to regulatory guidelines issued in November to combat monopolies in active medicinal ingredients (API), ingredients that China leads in manufacturing and exporting.
The Ministry said in a statement that it will "strengthen law enforcement against unfair competition, and resolutely investigate unfair competitive acts, such as commercial bribery".
It will also strengthen anti-monopoly enforcement in the areas of drug shortages and APIs, draft and approve antitrust rules in the API market, and probe monopolistic pacts, according to the statement.
